| Literature DB >> 36132901 |
Maxi B Paul1, Valerie Stock1, Julia Cara-Carmona1, Elisa Lisicki1, Sofiya Shopova1, Valérie Fessard2, Albert Braeuning1, Holger Sieg1, Linda Böhmert1.
Abstract
The production and use of plastics has constantly increased over the last 30 years. Over one third of the plastics is used in disposables, which are discarded within three years of their production. Despite efforts towards recycling, a substantial volume of debris has accumulated in the environment and is slowly degraded to micro- and nanoplastics by weathering and aging. It has recently been discovered that these small particles can enter the food chain, as for example demonstrated by the detection of microplastic particles in honey, beer, salt, sea food and recently in mineral water. Human exposure has further been documented by the detection of plastic microparticles in human feces. Potential toxic consequences of oral exposure to small plastic particles are discussed. Due to lacking data concerning exposure, biodistribution and related effects, the risk assessment of micro- and nanoplastics is still not possible. This review focuses on the oral uptake of plastic and polymer micro- and nanoparticles. Oral exposure, particle fate, changes of particle properties during ingestion and gastrointestinal digestion, and uptake and transport at the intestinal epithelium are reviewed in detail. Moreover, the interaction with intestinal and liver cells and possibly resulting toxicity are highlighted. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 36132901 PMCID: PMC9417819 DOI: 10.1039/d0na00539h
Source DB: PubMed Journal: Nanoscale Adv ISSN: 2516-0230
Fig. 1Challenges and pitfalls in the field of micro- and nanoplastics research.
Fig. 2Human exposure and the path of micro- and nanoplastic particles in the human body.
Summary of the reviewed literature using in vitro models to study the effect of micro- and nanoplastics
| Reference | Cell model & particles used | Results |
|---|---|---|
|
| ||
| Wu | - Caco-2 cell model | - No cytotoxicity |
| - PS: 100 & 500 nm | - Weak toxic effects on oxidative stress and membrane integrity | |
| - 1–200 μg mL−1 | - Disruption of mitochondrial membrane potential, especially with 500 nm PS | |
| - Inhibition of plasma membrane-located ABC transporter in 100 nm PS | ||
|
| ||
| Magri | - Caco-2 cell model | - No cytotoxicity, no LDH release |
| - PET: 100 nm, laser ablated, different characteristics | - Cellular uptake near lysosomes | |
| - 1-30 μg mL−1 | - After 24 h transport across Caco-2 layer was visible, 3% transported | |
| - No toxic effects after 24 h | ||
| Stock | - Caco-2 monoculture | - Toxicity only in unphysiological concentrations with 1 μm PS(−) |
| - Caco-2/Raji B M-cell model | ||
| - Caco-2/HT29-MTX mucus model | - Minimal uptake, highest with 4 μm (max. 3%), small differences between models | |
| - PS: 1 μm, carboxylated | ||
| - PS: 4 & 10 μm, sulfonated | - Macrophage polarization → no impacts on polarization or differentiation | |
| - 1 × 103 to 1 × 1010 μm2 surface particles per mL | ||
| Hesler | - Caco-2/HT29-MTX mucus model | - No cytotoxicity |
| - PS: 50 & 500 nm | - No significant transport across barrier | |
| - Carboxylated | - Intercellular distribution of particles | |
| - 0.01-100 μg mL−1 | - Cellular uptake: Internalized cells were visible with electron microscopy | |
| Abdelkhaliq | - Caco-2 cell model | - No cytotoxicity |
| - PS: 50 nm & 200 nm | - Minimal transport, ranging from 2.82% (50 nm (carboxylated)) to 13.9% (50 nm (sulfonated)) | |
| - Carboxylated or sulfonated | - Composition of protein corona & surface of PS influence cellular uptake and transport | |
| - 15–250 μg mL−1 | ||
| Stock | - Inversed cell culture model for low-density particles with HepG2 | - Cytotoxicity only in overload situations |
| - PE: polydisperse | ||
| - 25-100 μg mL−1 | ||
| Lehner | - Caco-2/HT29-MTX co-culture with human blood monocyte-derived macrophages and dendritic cells | - No cytotoxicity |
| - PP, PU, PA, tire rubber polydisperse | - No release of inflammatory cytokines | |
| - No changes in barrier integrity | ||
Summary of the reviewed literature using in vivo models to study the effect of micro- and nanoplastics
| Reference | Study & particles used | Main findings | Comments |
|---|---|---|---|
|
| |||
| Deng | - 28 days mice study | - Tissue accumulation in liver, kidney, gut | - For critical comments refer to |
| - PS 5 & 20 μm | - Inflammation and lipid accumulation in liver | ||
| - 0.01, 0.1, 0.5 mg per day | |||
| - Daily oral gavage | - Oxidative stress in liver | ||
| Lu | - 5 week mice study | - Hepatic metabolism & gut microbiota disorder | |
| - PS: 0.5 & 50 μm | - Decrease of colonic mucus secretion & serum triglycerides | - Partly from the same authors like Luo | |
| - 100 & 1000 μg L−1 (about 1.456 × 1010 particles per L for 0.5 μm and 1.456 × 104 particles per L for 50 μm) | |||
| - Direct drinking with continuous exposure for 5 weeks | |||
| - Particles were used as received | - Water input not detected, unknown amount of PS intake | ||
| - Basic diet | |||
| Jin | - 6 week mice study | - Increase of bile acids and their metabolites in liver | |
| - PS: 5 μm | - Decrease of mucus secretion in colon | ||
| - 100 μg L−1 (approximately 1.456 × 106 particles per L) 1000 μg L−1 (approximately 1.456 × 107 particles per L) | - Control group received water | ||
| - Direct drinking with continuous exposure for 6 weeks | |||
| - Particles were used as received, stock solutions were treated with ultrasound for 30 min | |||
| - Basic diet | |||
| Luo | - Mice study with maternal & offspring (F1, F2) mice | - Changes in serum and hepatic markers | - Partly from the same authors like Lu |
| - PS: 0.5 & 5 μm | - Fatty acid and metabolic disorders in F1 offsprings | - Water input not detected, unknown amount of PS intake | |
| - 100 & 1000 μg L−1 | - Gut microbiota dysbiosis and barrier dysfunction | ||
| - Maternal exposure during gestation (from GD 0 to production day) through drinking water, F1 & F2: No gavage | - Unknown feed supply | ||
| - Particles were used as received, stock solutions were treated with ultrasound for 30 min | |||
| Luo | - PS: 5 μm | - Maternal metabolic disorder associated with gut microbiota dysbiosis and gut barrier dysfunction | - Control group received water |
| - 100 & 1000 μg L−1 | |||
| - Maternal exposure during pregnancy and lactation (∼6 weeks) through drinking water, F1 & F2: No gavage | |||
| - Particles were used as received, stock solutions were treated with ultrasound for 30 min | - Long-term metabolic consequences in the F1 and F2 generations | ||
|
| |||
| Stock | - 28 days HOTT mice study | - Minor uptake in intestinal cells | - Different type of particle administration |
| - PS mixture: 1, 4 & 10 μm | - Mice had altered genetic background | ||
| - 4.55 × 107 & 1.49 × 106 particles, 10 mL per kg per bw | - No bioaccumulation in different tissues | ||
| - Oral gavage 3× per week | - No inflammation, oxidative stress or toxic effects | ||